Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 4/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | BRD2 | P25440 | 2/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682216 | 0.89 | SMN1; SMN2 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL16058831 | 0.87 | MAPK1 (0.67) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL381684 | 0.86 | PDE4A (0.71) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL10955005 | 0.84 | MAPK1 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL1495090 | 0.84 | PDE4A (0.76) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL10856071 | 0.84 | MAPK1 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL10860941 | 0.84 | MAPK1 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL7999341 | 0.84 | MAPK1 (0.59) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL10112859 | 0.84 | ADORA2B (0.62) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA | |
| SCHEMBL10335113 | 0.83 | SMN1; SMN2 (0.64) | MAPK1CYP3A4PMP22SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403826-B2 | Compositions and methods for the treatment of inflammatory disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-9403826-B2 | Compositions and methods for the treatment of inflammatory disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-20150119409-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119409-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119409-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | BRCA1, PTGER1, EPAS1 | MAPK1 1412/4885CYP3A4 592/4885PMP22 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.